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To portray Usher Syndrome type 2, analyzing choroidal thickness and comparing data reported in published literature on RP
and healthy subjects. Methods. 20 eyes of 10 patients with clinical signs and genetic diagnosis of Usher Syndrome type 2. Each
patient underwent a complete ophthalmologic examination including Best Corrected Visual Acuity (BCVA), intraocular pressure
(IOP), axial length (AL), automated visual field (VF), and EDIOCT. Both retinal and choroidal measures weremeasured. Statistical
analysis was performed to correlate choroidal thickness with age, BCVA, IOP, AL, VF, and RT. Comparison with data about healthy
people and nonsyndromic RP patients was performed. Results. Mean subfoveal choroidal thickness (SFCT) was 248.21 ± 79.88
microns. SFCT was statistically significant correlated with age (correlation coefficient −0.7248179, 𝑝 < 0.01). No statistically
significant correlation was found between SFCT and BCVA, IOP, AL, VF, and RT. SFCT was reduced if compared to healthy
subjects (𝑝 < 0.01). No difference was found when compared to choroidal thickness from nonsyndromic RP patients (𝑝 = 0.2138).
Conclusions. Our study demonstrated in vivo choroidal thickness reduction in patients with Usher Syndrome type 2.These data are
important for the comprehension of mechanisms of disease and for the evaluation of therapeutic approaches.
1. Introduction
The choroid plays several important functions within the eye,
providing metabolic support to retinal pigment epithelium
(RPE) and outer retina, contributing to the blood vascular-
ization of the preliminary portion of the optic nerve and
absorbing excess of light entering the retina and RPE thanks
to the presence of melanocytes.
The choroid cannot be excluded in the evaluation
and understanding of the pathophysiological mechanisms
responsible for diseases of the posterior segment.
Many experiments and clinical studies have shown both
retinal and choroidal altered blood flow in Retinitis Pigmen-
tosa (RP) [1–3]. Clinically, the retinal vessels reduction is a
pathognomonic finding in RP and the value of retinal blood
flow measurement is significantly reduced in RP patients
compared to that in healthy subjects [2]. Similarly in patients
with RP, the ocular pulse amplitude (OPA), an indirect
measure of choroidal perfusion, was significantly reduced in
the advanced stages of the disease [4]. However, the role that
these perfusion abnormalities have in the pathogenesis of RP
is still uncertain.
The recent development of the technique Enhanced
Depth Imaging (EDI) [5, 6], which allows through the use
of Spectral Domain OCT obtaining detailed images of the
choroid, has given substantial impetus to the study of the
physiopathological role of choroid such as physiological vari-
ation with age and implication in pathogenic mechanisms.
In RP, the analysis of choroidal thickness has a double
importance; while it is an important additional factor for the
understanding of the pathogenesis and course of the disease,
it is an essential element in the evaluation of therapeutic
perspectives, like retinal implants, gene therapy, and stem
cells therapy.
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Table 1: USH2A gene mutations in our Usher patients cohort.
Patient Mutation Genotype
1 c.10450C>T c.2276G>T Heterozygous
2 c.5776+1G>C Homozygous
3 c.1663C>G c.2276G>T Heterozygous
4 c.2276G>T c.1663C>G Heterozygous
5 c.1434G>C c.4106C>T Heterozygous
6 c.2898delG Homozygous
7 c.11864G>A c.4714C>T Heterozygous
8 c.2299delG c.1606T>C Heterozygous
9 c.1751G>T c.2276G>T Heterozygous
10 c.2299delG c.14074G>A Heterozygous
Retinitis Pigmentosa is also a term that embraces a mul-
titude of clinical conditions that have similar characteristics
but differ for age of onset, course, and severity.
The aim of the study is to portray the most common
syndromic form of RP, Usher Syndrome type 2, analyzing the
thickness of the choroid in correlation with disease stage and
comparing values reported in literature on nonsyndromic RP
and healthy subjects.
2. Methods
All patients were recruited from the hereditary retinal dis-
eases service at the University Eye Clinic of San Paolo Hos-
pital in Milan between January and May 2014. They are part
of a larger group of Usher Syndrome patients being evaluated
at our clinic. Diagnosis of Usher Syndrome was confirmed
by both clinical signs (characteristic bone spicule pigmenta-
tion, optic disc pallor, retinal vessel attenuation, visual field
constriction, flat electroretinographic waves, photoreceptor
atrophy shown by OCT, and bilateral sensorineural hearing
loss) and results of genetic analysis.
We considered for the present study patients with at least
one homozygous mutation or two heterozygous mutations.
Heterozygous mutations have been confirmed on the two
alleles by segregation analysis (Table 1).
All participants underwent a complete ophthalmologic
examination includingBest CorrectedVisualAcuity (BCVA),
intraocular pressure, axial length, automated visual field, and
EDI OCT.
Demographic data and medical history (including the
age of diagnosis of Usher Syndrome, the first symptoms
onset, and the presence/absence of other members of the
family affected by the same disease) were collected using a
questionnaire that all the patients were asked to complete
before the inclusion in the study. Duration of disease was
considered from the date of first diagnosis.
Factors that have been demonstrated to influence
choroidal thickness (refractive error > 6 diopters and
elongated axial length) or poor OCT scan quality (media
opacities, nystagmus) were considered noninclusion criteria.
Other exclusions included history of glaucoma or uveitis,
prior ocular surgery (excepted cataract surgery), systemic
cardiovascular disease like hypertension, and diabetes.
We arbitrarily considered 3 stages of disease according to
the parameters of visual acuity and visual field: stage 1 for
patients with visual acuity better than 0.6 decimal or visual
field mean defect less than 10 dB, stage 2 for patients with
visual acuity from 0.6 to 0.2 decimal or visual field mean
defect from 10 to 20 dB, and stage 3 for patients with visual
acuity less than 0.2 decimal or visual field mean defect more
than 20 dB.
2.1. Automated Visual Field. Visual field analysis was
obtained using the 30-2 SITA standard program of the
Humphrey Visual Field Analyzer (Zeiss/Humphrey Systems,
Dublin, CA, United States).
Examinations were performed using the best correction
for near vision. For the purpose of the study mean defect
(MD) and Pattern Standard Deviation (PSD) values were
considered.
2.2. Axial Length. Axial length was measured using the IOL
Master 500 biometer (Carl ZeissMeditec, Dublin, CA,United
States). The values used for the study were obtained from the
mean of five consecutive measures.
2.3. Enhanced Depth Imaging Optical Coherence Tomography
(EDI OCT). Retinal and choroidal imaging were obtained
using Spectralis HRA and OCT (Heidelberg Engineering,
Heidelberg, Germany). EDI OCT technique, previously
described by Spaide and Margolis [5, 6], allows detailed
imaging of the choroidal layer. For the study we took single
line scans of 30∘ composed of 100 averaged images using
the automatic eye tracking software across the fovea both
vertically and horizontally.
Both retinal and choroidalmeasures were takenmanually
in a masked fashion by two experienced OCT-readers as
shown in Figure 1. Choroidal thickness was measured as pre-
viously described by Dhoot et al. [7]: from the inner border
of the sclera to the outer border of the RPE vertically using
the calipers of the Heidelberg reader software subfoveally
and at 500mm intervals for 2.5mmnasal, temporal, superior,
and inferior to the centre of the fovea. Retinal thickness was
taken in the same intervals vertically from the outer border
of the RPE to the inner border of ILM. Horizontal spatial
distribution of photoreceptor layer was manually measured
using the calipers. Also presence/absence of cystoid macular
edema was considered.
All scans were performed with dilated pupils (using 1%
tropicamide).
Only OCT scans of good quality were used for the
measures (Figure 1).
2.4. Statistics. Data were analyzed using a Mixed Effect
Model (MEM) approach. First, we studied the correlation
between choroidal thickness and retinal thickness in the
foveal region with a series of predictors (age, time from
first symptoms, axial length, BCVA, MD, and PSD as con-
tinuous variables, presence of photoreceptors, and presence
of oedema as categorical variables). Correlation between
choroidal thickness and retinal thickness was also calculated.
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Figure 1: Horizontal (a) and vertical (b) choroidal and retinal measurements were taken manually in a masked fashion by two experienced
OCT-readers. Values in the black boxes represent the topographic location of each measurement (T = temporal, N = nasal, S = superior, I =
inferior, and SFCT = subfoveal choroidal thickness).
All correlations were calculated using univariate MEMmod-
els where a patient random effect was included to account
for the covariance among observations from the same subject
(i.e., two measurements from each patient, one for each eye).
Secondly, we analyzed the effect of the age of the patients
on the choroidal thickness at various distances from the
fovea (every 0.5 microns from −2.5 to 2.5 microns away) on
both temporal-nasal and superior-inferior axes. In this case
a multivariate MEM analysis was used. Age and the site of
measurement were treated as fixed effects; a patient and an
eye random effect were used to correct for the covariance
among observations from the same patient and the same eye
(i.e., multiple measurements from each eye of each patient).
Finally, an interaction term was included to allow different
slopes in themodel at each site.The different slopes were used
to create a correlationmap showing the effect of the age of the
patient on the choroidal thickness at each site.
𝑍-test analysis was used to compare our data on choroidal
thickness in patients with Usher Syndrome type 2 with values
of choroidal thickness in healthy and nonsyndromic RP
patients as reported in published literature.
Table 2: Demographic data.
Demographic data Mean Standard deviation
Age (years) 43.10 ±14.09
Duration of disease (years) 17.80 ±12.28
Visual acuity (decimal) 0.66 ±0.37
Spherical equivalent (diopters) −3.50 ±2.50
Axial length (mm) 23.59 ±1.29
3. Results
10 patients (20 eyes) with clinical and genetic diagnosis of
Usher Syndrome type 2 were included in the study (4 men
and 6women).Themean age was 43.1±13.09 years; themean
duration of disease was 17.8 ± 12.28 years.
Mean BCVAwas 0.66 decimal, ranging between 0.05 and
1. Spherical equivalent ranged from −3.5D to +2.5D and
mean axial length was 23.59 ± 1.29mm (Table 2).
Mean subfoveal choroidal thickness (SFCT) (Table 3) was
237.45 ± 76.81 microns, with a mean choroidal thickness
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Table 3: Mean choroidal thickness values at different sites (values
are in microns).
Choroidal thickness Mean Standard deviation
Subfoveal 237.45 76.81
0.5mm nasal 230.85 88.85
1.0mm nasal 212.40 81.47
1.5mm nasal 176.70 67.74
2.0mm nasal 151.00 62.79
2.5mm nasal 130.20 65.34
0.5mm temporal 242.75 76.53
1.0mm temporal 231.90 70.39
1.5mm temporal 223.30 62.34
2.0mm temporal 205.65 59.53
2.5mm temporal 194.60 63.41
0.5mm superior 233.40 71.61
1.0mm superior 227.60 71.63
1.5mm superior 220.90 74.97
2.0mm superior 219.50 57.82
2.5mm superior 219.75 64.19
0.5mm inferior 228.40 75.70
1.0mm inferior 222.20 74.19
1.5mm inferior 209.45 71.62
2.0mm inferior 202.95 64.94
2.5mm inferior 200.10 67.79
thinner 2.5mm nasally than 2.5mm temporally to the fovea
(130.2 and 194.6mm, resp.) and 2.5mm inferiorly than
2.5mm superiorly to the fovea (200.1 and 219.75mm, resp.).
Mean foveal retinal thickness was 214.75±75.72microns.
The mean retinal thickness was thinner 2.5mm temporally
than 2.5mm nasally to the fovea (199.9 and 223.85mm, resp.)
and 2.5mm inferiorly than 2.5mm superiorly to the fovea
(209.35 and 222.55mm, resp.).
25% of the eyes (5/20) presented CME. In 15% of the eyes
(3/20) photoreceptors outer segment layer was not detectable
at OCT. When detectable, the mean horizontal extension of
photoreceptor layer (concentric to the fovea) was 264.7 ±
148.71microns.
SFCT was significantly correlated with age: SFCT
decreases with age (estimated coefficient −4.412, Pearson
correlation coefficient −0.725, 𝑝 < 0.01). No statistically
significant correlationwas found between SFCT and duration
of disease, different stages of disease (as evaluated with visual
acuity and visual field parameters), retinal thickness, and
axial length (Table 4).
We then analyzed the correlation between choroidal
thickness and age in each interval: Figure 2 shows the
intervals in which the correlation was significantly different
from that of the fovea. The intervals further away from the
fovea were less correlated with age (the values indicated with
the asterisks).
Choroidal thickness values from Usher patients were
compared with values reported in published literature for
healthy subjects and nonsyndromic RP patients. Choroidal
thickness in Usher patients was significantly reduced when
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Figure 2: Correlation between the age of the patient and the
choroidal thickness at different sites. Circle radii are proportional to
the estimated correlation. Numbers represent the beta coefficients
of the multivariate model for age at different sites (calculated from
the interaction term in the model). Asterisks indicate in which sites
the correlation between choroidal thickness and age is significantly
different from the one found in the subfoveal region (chosen as the
reference level in the model).
compared to healthy subjects [6] (𝑝 < 0.01, 𝑍-test), while no
difference was found when compared to choroidal thickness
from nonsyndromic RP patients [8] (𝑝 = 0.72).
4. Discussion
Our case control study showed that choroidal thickness is
reduced in people with Usher Syndrome type 2 if compared
to healthy subjects [5, 6, 9, 10].
Our results confirmed those reported by Dhoot et al. [7],
who studied choroidal thickness in nonsyndromic RP using
the same strategy to analyze OCT images, by Ayton et al.
[8] who studied nonsyndromic RP patients using a graphic
software to analyze choroidal thickness in OCT scans and
by Yoon and Yu [11] who used a different instrument of
acquisition and analysis of OCT scans.
Both retinal vascularization and choroidal vasculariza-
tion were reported to be significantly reduced in RP patients
and in animal models of RP [1, 3, 4]: our observations can be
considered a sign of this blood flow reduction.
Correlation between choroidal thickness and course of
the disease remains unclear. Recent studies demonstrated dif-
ferent visual acuity, visual field, and cone electroretinogram
amplitude loss in Usher Syndrome patients if compared to
nonsyndromic type of RP [12]: comparison between our data
and choroidal thickness values in nonsyndromic RP reported
in literature could not explain these differences.
Although previous studies reported that choroidal arter-
ies and choriocapillaris under macular region fill more
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Table 4: Beta regression coefficients of subfoveal choroidal thickness on different predictors (univariate analysis). Each column corresponds
to a different regression analysis showing the estimated regression coefficient and, in brackets, the corresponding standard error. Asterisks
represent the significance according to the legend on the bottom. Among tested variables, age is the only significant predictor of the subfoveal
choroidal thickness.
Dependent variable: subfoveal choroidal thickness
Retinal
thickness Age
Duration of
disease
Axial
length BCVA MD PSD Photoreceptors Edema
Coefficients 0.093 −4.412
∗∗∗
−1.475 0.046 28.314 1.585 13.075 −41.027 −8.168
(0.216) (1.370) (2.151) (19.061) (68.411) (3.608) (8.391) (35.597) (34.146)
Intercept 228.185
∗∗∗ 437.738∗∗∗ 273.859∗∗∗ 246.514 228.984∗∗∗ 288.786∗∗∗ 157.069∗∗ 253.754∗∗∗ 249.642∗∗∗
(51.328) (61.449) (45.756) (450.333) (51.608) (97.277) (64.992) (23.881) (26.223)
Observations 20 20 20 20 20 20 20 20 20
Note.; ∗∗𝑝 < 0.05; ∗∗∗𝑝 < 0.01.
rapidly and intensely compared to other retinal locations,
supporting the concept that thicker choroidal thickness
under the fovea is due to macular higher metabolic request
[13]; however, similarly to Yeoh et al. [14] and Dhoot et al.
[7], our study did not show any correlation between SFCT
and visual acuity. We also could not find any correlation
between SFCT and presence/absence of outer retinal layer or
macular edema. A possible explanation of these data could
be that EDI OCT technique does not allow distinguishing
choriocapillaris, which represents about 10% of all choroidal
thickness [15, 16], from the rest of choroidal volume. We are
not able to understand which role choriocapillaris plays in
this degenerative process.
First publications by Spaide and Margolis on choroidal
thickness in healthy subjects reported a decrease of choroidal
thickness with age [5, 6]. Similarly our study found a
statistically significant correlation: also in patients withUsher
Syndrome type 2 SFCT decreases with age. On the other
hand, no correlation between SFCT and duration of disease
was found, in contrast with Ayton’s previous report [8]. This
observation could be due to the fact that it is difficult to
establish the exact onset of the disease: for the majority of
patients diagnosis follows symptoms onset and in addition
to that considering that Usher Syndrome is a genetic disease
the concept of duration of disease is not as relevant as
chronological age.
Interestingly in our Usher Syndrome study group the
topographic choroidal thickness variation appears to be sim-
ilar to topographic choroidal thickness variation previously
reported in literature for healthy subject [17]. Choroidal
thickness was thinner in nasal than in temporal sector and
in inferior than superior sector. Furthermore we evaluated
the correlation between choroidal thickness and age in each
topographic sector: as shown in Figure 2 intervals far from
the fovea resulted in being statistically less associated with
age if compared to the fovea. This fact could be reasonably
explained by the fact that central retina, particularly the fovea,
is the last involved with the degenerative process in rod-cone
dystrophy. To our knowledge, the relationship between the
thickness of the choroid in different regions of themacula and
the correlation with topographic variations has not yet been
described.
Lack of correlation between choroidal thickness and axial
length could be explained by the small number of patients
studied and by the fact that we considered an exclusion
criteria refractive error > 6 diopters.
In conclusion we have demonstrated in vivo choroidal
thickness reduction in different topographic sectors in
patients with Usher Syndrome type 2. These data are
important not only for the comprehension of pathogenetic
mechanisms in hereditary retinal diseases but also for the
evaluation of therapeutic approaches. A deep knowledge
of residual choroidal blood flow and changes in choroidal
vascularization would be necessary for both retinal implant
and stems cells therapy.
Limits of our study are represented by the small number
of patients and the absence of a healthy and a nonsyndromic
RP control group.
Further studies will need to investigate the correlation
between different type of RP, classified by genetic mutation,
and choroidal changes. New and more sophisticated OCT
techniques will allow better understanding of the role that
the choroid plays in the pathogenesis of hereditary retinal
diseases.
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